Trial Profile
A Phase I Study of ADG106 Administered in Patients With Advanced or Metastatic Solid Tumors and/or Non-Hodgkin Lymphoma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 26 Apr 2023
Price :
$35
*
At a glance
- Drugs ADG 106 (Primary)
- Indications Adenocarcinoma; Follicular lymphoma; Mesothelioma; Nasopharyngeal cancer; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Solid tumours
- Focus Adverse reactions
- Sponsors Adagene
- 20 Apr 2023 Status changed from active, no longer recruiting to completed.
- 15 Oct 2022 Planned End Date changed from 31 Aug 2022 to 31 Dec 2022.
- 22 Jul 2022 Planned End Date changed from 28 Feb 2022 to 31 Aug 2022.